Moffitt Cancer Center | Strategic Alliance Partners

August 26, 2016

Richard Levine, MD, discusses the selection of therapies available for patients with metastatic castration-resistant prostate cancer and the next steps in the field.

August 26, 2016

Kosj Yamoah, MD, discusses health disparities in prostate cancer and unanswered questions researchers still need to tackle.

August 25, 2016

Julio Pow-Sang, MD, discusses the significance of assessing risk status, options for patients with prostate cancer whose risk status falls in a "grey-zone," and how technology is helping oncologists more accurately characterize risk.

August 25, 2016

Jingsong Zhang, MD, PhD, discusses his vision for treating patients with metastatic castration-resistant prostate cancer.

August 24, 2016

Michael Poch, MD, provides deeper insight into how immunotherapy has propelled the field of bladder cancer forward, as well as the research that still needs to be done.

August 24, 2016

Mayer Fishman, MD, discusses the therapeutic landscape in renal cell carcinoma and the next steps needed to further advance the field.

August 23, 2016

Conor Lynch, PhD, sheds light on the biology of bone metastases as well as the mechanism of action for bone-directed therapies for patients with metastatic castration-resistant prostate cancer.

August 22, 2016

Heather Jim, MD, describes the psychological impacts of testosterone-lowering drugs for patients with prostate cancer—and what oncologists should do to help.

August 19, 2016

Peter Johnstone, MD, provides insight on post-prostatectomy radiation therapy for patients with prostate cancer.

August 16, 2016

Mayer Fishman, MD, PhD, medical oncologist, Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center, professor, Department of Oncologic Sciences and of Internal Medicine, University of South Florida Morsani College of Medicine, discusses the available agents to treat patients with renal cell carcinoma.

June 27, 2016

Morganna Freeman, DO, explains the impact of hedgehog inhibitors in basal cell carcinoma, the ideal patient to receive them, and emerging agents on the horizon for treatment of the disease.

May 27, 2016

Perry Kennedy, PhD, discusses the goals of the RAS Initiative.

April 06, 2016

Jessica Frakes, MD, explains findings from a study that examined treatment and follow-up for HPV-associated oropharynx cancer, and how they could impact clinical practice for the follow-up of patients with the disease.

March 07, 2016

Researchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.

December 22, 2015

Frederick Locke, MD, discusses the potential for KTE-C19 in non-Hodgkin lymphoma.

October 16, 2015

Dr. Ben Creelan, discusses the impact of the expanded approval of nivolumab in NSCLC and how the drug compares with pembrolizumab.

October 05, 2015

The ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.

June 25, 2015

Treatment with CPX-351 led to a relative improvement in induction response of over 40% compared with conventional 7+3 cytarabine/daunorubicin in patients with secondary acute myeloid leukemia.

June 18, 2015

Nagi B. Kumar, PhD, Professor/Director, Cancer Chemoprevention, Moffitt Cancer Center, discusses the potential of green tea catechins for the prevention of prostate cancer.

May 26, 2015

To better understand the impact of the EORTC 18071 trial, the chances of approval in the adjuvant setting, and the challenges concerning the dosage and toxicity with ipilimumab, OncLive spoke with the study's lead author Jeffrey S. Weber, MD, PhD.